SEOM clinical guidelines for the treatment of metastatic breast cancer

被引：6

作者：

Alvarez Lopez, Isabel ^{[1
]}

de la Haba Rodriguez, Juan ^{[2
]}

Ruiz Simon, Amparo ^{[3
]}

Bellet Ezquerra, Meritxell ^{[4
]}

Calvo Martinez, Lourdes ^{[5
]}

Garcia Estevez, Laura ^{[6
]}

Rodriguez Lescure, Alvaro ^{[7
]}

Isla Casado, Dolores ^{[8
]}

机构：

[1] Hosp Donostia, Serv Oncol Med, ES-20014 Donostia San Sebastian, Spain

[2] Hosp Univ Reina Sofia, Serv Oncol Med, Cordoba, Spain

[3] Inst Valenciano Oncol, Serv Oncol Med, Valencia, Spain

[4] Hosp Gen Valle Hebron, Serv Oncol Med, Barcelona, Spain

[5] Complejo Hosp Univ, Serv Oncol Med, La Coruna, Spain

[6] Ctr Integral Oncol Clara Campal, Serv Oncol Med, Madrid, Spain

[7] Hosp Gen Univ Elche, Serv Oncol Med, Alicante, Spain

[8] Hosp Clin Univ Lozano Blesa, Serv Oncol Med, Zaragoza, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2010年 / 12卷 / 11期

关键词：

Metastatic; Breast; Cancer; Diagnostic; Treatment; POSTMENOPAUSAL WOMEN; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; PHASE-II; CHEMOTHERAPY; TRASTUZUMAB; PACLITAXEL; THERAPY; PLUS; METAANALYSIS;

D O I：

10.1007/s12094-010-0585-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with metastatic breast cancer have a wide number of treatment options, including medical, surgical, and supportive care measures. Treatment decisions are based in predictive and prognostic factors and the informed choice of the patients. SEOM has elaborated these guidelines with evidence-based recommendations for the diagnostic work-up, treatment (chemotherapy, endocrine therapy and targeted therapies) and supportive care for the management of these patients.

引用

页码：719 / 723

页数：5

共 18 条

[1] Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer:: A Spanish breast cancer research group (GEICAM-9903) phase III study [J].

Alba, E ;

Martín, M ;

Ramos, M ;

Adrover, E ;

Balil, A ;

Jara, C ;

Barnadas, A ;

Fernández-Aramburo, A ;

Sánchez-Rovira, P ;

Amenedo, M ;

Casado, A .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2587-2593

[2] Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) in patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC) [J].

Baselga, J. ;

Climent, M. A. ;

Lluch, A. ;

Hornedo, J. ;

Gascon, R. ;

Sanchez, A. T. ;

Guillem, V. ;

Cortes-Funes, H. ;

Regueiro, P. ;

Trigo, J. .

EJC SUPPLEMENTS, 2004, 2 (03) :132-132

[3] Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients [J].

Bruzzi, P ;

Del Mastro, L ;

Sormani, MP ;

Bastholt, L ;

Danova, M ;

Focan, C ;

Fountzilas, G ;

Paul, J ;

Rosso, R ;

Venturini, M .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5117-5125

[4] Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer [J].

Burstein, HJ ;

Kuter, I ;

Campos, SM ;

Gelman, RS ;

Tribou, L ;

Parker, LM ;

Manola, J ;

Younger, J ;

Matulonis, U ;

Bunnell, CA ;

Partridge, AH ;

Richardson, PG ;

Clarke, K ;

Shulman, LN ;

Winer, EP .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2722-2730

[5] Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT [J].

Chia, Stephen ;

Gradishar, William ;

Mauriac, Louis ;

Bines, Jose ;

Amant, Frederic ;

Federico, Miriam ;

Fein, Luis ;

Romieu, Gilles ;

Buzdar, Aman ;

Robertson, John F. R. ;

Brufsky, Adam ;

Possinger, Kurt ;

Rennie, Pamela ;

Sapunar, Francisco ;

Lowe, Elizabeth ;

Piccart, Martine .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1664-1670

[6] Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma - Results from the gruppo oncologico nord ovest randomized trial [J].

Conte, PF ;

Guarneri, V ;

Bruzzi, P ;

Prochilo, T ;

Salvadori, B ;

Bolognesi, A ;

Aldrighetti, D ;

Venturini, M ;

Rosso, R ;

Mammoliti, S ;

Carnino, F ;

Giannessi, P ;

Costantini, M ;

Moyano, A ;

Baldini, E .

CANCER, 2004, 101 (04) :704-712

[7]

ELLIS M, 2008, ENDOCRINE THERAPY ME

[8]

Ellis M., 2000, DIS BREAST, P749

[9] Lapatinib plus capecitabine for HER2-positive advanced breast cancer [J].

Geyer, Charles E. ;

Forster, John ;

Lindquist, Deborah ;

Chan, Stephen ;

Romieu, C. Gilles ;

Pienkowski, Tadeusz ;

Jagiello-Gruszfeld, Agnieszka ;

Crown, John ;

Chan, Arlene ;

Kaufman, Bella ;

Skarlos, Dimosthenis ;

Campone, Mario ;

Davidson, Neville ;

Berger, Mark ;

Oliva, Cristina ;

Rubin, Stephen D. ;

Stein, Steven ;

Cameron, David .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26) :2733-2743

[10] American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer [J].

Hillner, BE ;

Ingle, JN ;

Chlebowski, RT ;

Gralow, J ;

Yee, GC ;

Janjan, NA ;

Cauley, JA ;

Blumenstein, BA ;

Albain, KS ;

Lipton, A ;

Brown, S .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :4042-4057

← 1 2 →